BioSpace News Archive

Surmodics, Inc., a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting of Shareholders on Thursday, February 11, at 4:00 p.m. CT, as a virtual meeting.

Stella Diagnostics, Inc . (OTC PINK:JMDP) announced today that they have entered into a partnership with mProbe, Inc., a leading biotechnology company based in California.

- Simple osmotic drive provides a low-cost bolus injection technology, allowing wearable devices to be applied to a broader range of drugs - Meets growing demand for large-volume injectors to reduce injection frequency - Easy to use, prefilled device supports in-home medication delivery, potentially moving more treatments out of hospital settings

Financing from new and existing investors to advance two European-approved antibiotics for the U.S. market Pivmecillinam Pre-NDA meeting with the FDA scheduled for April 2021 LONDON, UK / ACCESSWIRE / February 4, 2021 / UTILITY therapeutics Ltd., a biotechnology company focused on the U.S. development and commercialization of two European-approved antibiotics for the treatment of urinary tract infections (UTI), announced the completion of a capital raise and provided corporate objecti

Surface Ophthalmics, Inc., a pharmaceutical company focused on the development and commercialization of innovative therapeutics for ocular diseases, today announced that the first patient has been dose

Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2020 fourth quarter and full year ended December 31, 2020 on Thursday, February 25, 2021 before the open of the U.S. financial markets.

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today provided an update on its progress towards potential approval and commercialization of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the treatment of wet AMD and other retinal diseases.

Evofem Biosciences, Inc., (NASDAQ: EVFM) and NCODA (National Community Oncology Dispensing Association, Inc.), are launching a collaboration to positively impact the quality of life for female patients living with, fighting and recovering from cancer by raising awareness about the importance and availability of a new non-hormonal birth control method, Phexxi®

Reistone Biopharma Co. Ltd. (“Reistone”), a clinical stage biopharmaceutical company focused on developing novel medicines for immuno-inflammatory, diseases with high unmet medical needs, today announced that SHR0302, an investigational selective Janus kinase type 1 (JAK1) inhibitor, met primary and key secondary endpoints in its Phase 2 Clinical Study (AMBER2)

Dascena, Inc., a machine learning diagnostic algorithm company that is targeting early disease intervention to improve patient care outcomes, today announced it is expanding its leadership team with the C-suite appointments of Jim Wingrove, Ph.D., as Chief Scientific Officer and David H. Ledbetter, Ph.D., as Chief Clinical Officer.